Experimental combo targets Hard-to-Treat pancreatic cancer
NCT ID NCT04132505
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested two drugs—binimetinib and hydroxychloroquine—in 34 people with a specific type of advanced pancreatic cancer (KRAS-mutant) that had spread. The goal was to find the safest dose of hydroxychloroquine when used with binimetinib, and to see if the combination could slow tumor growth. Participants had already tried at least one other treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a targeted antibody give pancreatic cancer chemo a boost?
- Can High-Dose vitamin c boost chemo against pancreatic cancer?
- Could a nerve zap stop cancer wasting? early trial tests device for cachexia
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer